Novo Nordisk to invest $158M in insulin plant

Novo Nordisk plans to invest approximately $158 million into revamping its Montes Claros manufacturing facility in Minas Gerais, Brazil, Bloomberg reported Oct. 5. 

Advertisement

The plant is crucial for the company, producing 25% of its global insulin output. The modernization efforts aim to enhance production capabilities and incorporate sustainability projects that align with global environmental goals. 

Since its establishment in 2007, the Montes Claros facility has supplied insulin to Brazil’s national health system and has also served as an export hub for international markets. 

The modernization of the plant is expected to create new jobs and boost the local economy while reinforcing Novo Nordisk’s position as a leader in the global insulin market.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.